Check-Cap Priced, Nasdaq: CHEK

Developing an ingestible imaging capsule to detect colorectal cancer.

Industry: Health Care

Latest Trade: $1.88 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: -68.7%

Industry: Health Care

We are a clinical stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for colorectal cancer, or CRC.  While CRC is the second leading cause of death from cancer in the United States and is largely preventable with early detection, about one-half of Americans over the age of 50 do not undergo any form of CRC screening due in large part to the pain, discomfort and embarrassment related to current screening methods.  Unlike other structural screening methods that are designed to generate structural information of the colon for the detection of pre-cancerous polyps, such as optical colonoscopy, computed tomographic colonography, and other capsule-based technology, our imaging capsule is designed to be ingested without any cleansing of the colon and to travel through the gastrointestinal tract naturally while the patient continues his or her normal daily routine.  Furthermore, unlike the procedures for CRC imaging devices currently on the market, all of which require the patient to fast for several hours prior to administration, the procedure for the Check-Cap device is designed to enable patients to continue eating normally.  We believe that this solution will be attractive to both physicians and patients, thereby increasing the number of people willing to undergo screening for CRC.
more less
IPO News for Check-Cap
more
IPO Data
IPO File Date 12/23/2014
Offer Price $6.00
Price Range $6.00 - $8.00
Offer Shares (mm) 2.0
Deal Size ($mm) $12
IPO Data
IPO Date 02/18/2015
Offer Price $6.00
Price Range $6.00 - $8.00
Offer Shares (mm) 2.0
Deal Size ($mm) $12
Underwriters
more
Company Data
Headquarters Isfiya, Israel
Founded 2008
Employees 36
Website www.check-cap.com